第一条 为规范安琪酵母股份有限公司（以下简称"公司"）行为，提高股 东会议事效率，保证股东会依法行使职权，根据《中华人民共和国公司法》（以 下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上 市公司股东会规则》、《上市公司治理准则》（以下简称《治理准则》）和《安 琪酵母股份有限公司章程》（以下简称《公司章程》）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 安琪酵母股份有限公司股东会议事规则 (2025 年 4 月修订) 第一章 总 则 第三条 公司应当严格按照法律法规、《公司章程》及本规则的相关规定召 开股东会，保证股东能够依法行使权利。 董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当勤勉 尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在法律法规、《公司章程》及本规则规定的范围内行使 职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的六个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形的，临时股东会应当在 两个月内召开。 公 ...

证券代码：600298 证券简称：安琪酵母 公告编号：2025-042 号 安琪酵母股份有限公司 关于修改公司《股东大会议事规则》 有关条款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 安琪酵母股份有限公司（以下简称公司）于 2025 年 4 月 25 日召开第九届董事会第四十三次会议，审议通过了《关于修改公 司〈股东大会议事规则〉有关条款的议案》。根据《中华人民共 和国公司法》《上市公司股东会规则》《安琪酵母股份有限公司 章程》有关规定，结合公司实际，拟对公司《股东大会议事规则》 部分条款进行修改并更名为《股东会议事规则》。本次修改尚需 提交股东大会审议。具体修改内容如下： | 修改前 | | 修改后 | | --- | --- | --- | | 新增 | | 第二条 公司股东会的召集、提案、通 知、召开等事项适用本规则。 | | 第二章 | 股东大会的一般规定 | 删除 | | 第四条 | 股东大会分为年度股东大 | 第五条 股东会分为年度股东会和临时 | | 会和临时股东大会。年度股东大会每年 | | 股东 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 3,794,177,570.05, representing an increase of 8.95% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 370,112,142.65, up 16.02% year-on-year[3]. - Basic earnings per share increased to CNY 0.43, reflecting a growth of 16.22% from the previous year[3]. - Net profit for Q1 2025 was ¥386,961,034.27, representing a 17.30% increase from ¥329,930,836.25 in Q1 2024[19]. - Earnings per share for Q1 2025 were ¥0.43, compared to ¥0.37 in Q1 2024, reflecting a 16.22% increase[20]. - The company's net profit for Q1 2025 was CNY 56,044,517.32, a decrease of 15.5% compared to CNY 66,291,262.35 in Q1 2024[30]. - Operating profit for Q1 2025 was CNY 59,535,517.07, down from CNY 68,034,490.45 in the same period last year, reflecting a decline of approximately 6.9%[30]. Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY -254,204,269.87, a 61.44% increase compared to the previous year[3]. - Cash inflow from operating activities in Q1 2025 was ¥4,225,218,581.93, an increase from ¥3,686,904,437.13 in Q1 2024[22]. - The company's cash and cash equivalents decreased slightly to RMB 1.35 billion from RMB 1.38 billion, a decline of approximately 2.93%[12]. - Cash flow from operating activities in Q1 2025 was negative at CNY -298,682,429.39, slightly worse than the negative CNY -296,365,787.94 in Q1 2024[31]. - The net cash flow from financing activities for Q1 2025 was CNY -173,167,977.35, contrasting with a positive CNY 449,315,040.49 in Q1 2024[32]. - The company reported a net cash outflow from investing activities of CNY -245,491,536.96, compared to CNY -456,187,609.04 in the previous period[24]. - Investment activities generated a net cash flow of CNY -11,279,642.87 in Q1 2025, an improvement from CNY -55,241,739.87 in Q1 2024[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 22,401,664,103.95, a 3.08% increase from the end of the previous year[4]. - Current assets totaled RMB 10.04 billion, up from RMB 9.51 billion, indicating a growth of about 5.58%[13]. - Total liabilities reached RMB 10.63 billion, up from RMB 10.39 billion, which is an increase of about 2.30%[14]. - The total assets increased to CNY 16,025,528,727.43 as of March 31, 2025, compared to CNY 14,693,031,497.31 at the end of 2024, reflecting a growth of 9.1%[26]. - The total liabilities rose to CNY 8,008,992,132.99, up from CNY 6,753,515,867.85, indicating an increase of 18.5%[27]. - The total equity remained stable at approximately RMB 11.77 billion, with a slight decrease from RMB 11.74 billion[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,802[8]. - The largest shareholder, Hubei Angel Biotechnology Group Co., Ltd., held 38.07% of the shares, totaling 330,707,745 shares[9]. Investment and Expenses - Investment income surged by 59.36% year-on-year, primarily due to the disposal of a subsidiary[6]. - The company reported a significant reduction in financial expenses by 83.25%, attributed to increased foreign exchange gains during the reporting period[6]. - Research and development expenses for Q1 2025 were ¥137,004,716.96, slightly down from ¥144,443,397.45 in Q1 2024[19]. - The company's R&D expenses for Q1 2025 were CNY 69,318,539.12, a decrease from CNY 74,963,284.33 in Q1 2024[29].

Core Viewpoint - Anqi Yeast reported a net profit of 370 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 16.02% [1] Financial Performance - The company's revenue for the first quarter of 2025 reached 3.794 billion yuan, representing a year-on-year increase of 8.95% [1] - The net profit of 370 million yuan indicates a strong performance compared to the previous year [1]

Group 1 - The plant-based meat concept index rose by 1.06%, ranking 8th among concept sectors, with 12 stocks increasing in value, including "Good Idea" which hit the daily limit [1] - Leading stocks in the plant-based meat sector included "Spring Snow Food" and "Sobao Protein," which rose by 5.82% and 4.37% respectively [1] - The sector experienced a net inflow of 394 million yuan from main funds, with 13 stocks receiving net inflows, and "Good Idea" leading with a net inflow of 203 million yuan [2][3] Group 2 - The top net inflow rates for main funds were recorded by "Good Idea" at 25.69%, "Meiyingsen" at 13.84%, and "Spring Snow Food" at 13.60% [3] - The plant-based meat sector's performance was contrasted with other sectors, such as "PEEK Materials" which rose by 3.70% and "Digital Currency" which fell by 3.10% [2] - Stocks that faced declines included "Lingge Technology," "Hai Xin Food," and "Zun Ming Co.," which dropped by 5.94%, 3.77%, and 3.56% respectively [1][4]

安琪酵母股份有限公司 2024 年年度股东大会会议资料 2025 年 4 月 30 日 安琪酵母股份有限公司 2024 年年度股东大会会议议程 ● 会议召开时间：2025 年 4 月 30 日 ● 现场会议时间：2025 年 4 月 30 日下午 14:00 ● 网络投票时间：采用上海证券交易所网络投票系统，通 过 交 易 系 统 投 票 平 台 的 投 票 时 间 为 2025 年 4 月 30 日 的 9:15-9:25、9:30-11:30、13:00-15:00；通过互联网投票平台的 投票时间为 2025 年 4 月 30 日的 9:15-15:00。 ● 会议召开地点：公司一楼会议室 ● 会议召开方式：现场投票与网络投票相结合的方式 三、审议会议议案： 1.2024 年度董事会工作报告； 2.2024 年度监事会工作报告； 3.2024 年年度报告及其摘要； 4.2024 年度财务决算及 2025 年度财务预算报告； 5.关于续聘会计师事务所的议案； 6.2024 年度利润分配方案的议案； 7.2025 年度为控股子公司提供担保预计的议案； 8.2025 年度拟开展外汇风险和利率风险管理业务的议案； ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600298 证券简称：安琪酵母 公告编号：2025-037号 安琪酵母股份有限公司 2024年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 安琪酵母股份有限公司（以下简称公司）于2025年4月21日（星期一）上午9:30-11:30在上海证券交易所 上证路演中心（网址：http://roadshow.sseinfo.com/），以视频直播和网络文字互动方式召开了2024年度 业绩说明会。关于本次业绩说明会的召开事项，详见公司于2025年4月11日在上海证券交易所网站 （www.sse.com.cn）上披露的《安琪酵母股份有限公司关于召开2024年度业绩说明会的公告》（2025- 034号）。现将召开情况公告如下： 一、业绩说明会召开情况 2025年4月21日，公司董事长熊涛、总经理肖明华、独立董事涂娟、财务负责人覃光新、董事会秘书高 路出席了本次业绩说明会，与投资者进行互动交流和沟通，就投资者关注的问题在信息披露允许的范围 内进行了回答 ...

证券代码：600298 证券简称：安琪酵母 公告编号：2025-037 号 安琪酵母股份有限公司 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担法律责任。 安琪酵母股份有限公司（以下简称公司）于 2025 年 4 月 21 日（星期一）上午 9:30-11:30 在上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/），以视频直播和网络 文字互动方式召开了 2024 年度业绩说明会。关于本次业绩说明 会的召开事项，详见公司于 2025 年 4 月 11 日在上海证券交易所 网站（www.sse.com.cn）上披露的《安琪酵母股份有限公司关于 召开 2024 年度业绩说明会的公告》（2025-034 号）。现将召开 情况公告如下： 一、业绩说明会召开情况 2025 年 4 月 21 日，公司董事长熊涛、总经理肖明华、独立 董事涂娟、财务负责人覃光新、董事会秘书高路出席了本次业绩 说明会，与投资者进行互动交流和沟通，就投资者关注的问题在 信息披露允许的范围内 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company is expected to see a recovery in profit margins, with a positive outlook for long-term profit improvement [6] - In 2024, the company achieved total revenue of 15.197 billion yuan, a year-on-year increase of 11.86%, and a net profit attributable to shareholders of 1.325 billion yuan, a year-on-year increase of 4.07% [2][4] - The company anticipates net profits of 1.602 billion yuan, 1.844 billion yuan, and 2.077 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.84, 2.12, and 2.39 yuan [6] Summary by Sections Financial Performance - In Q4 2024, the company reported total revenue of 4.285 billion yuan, a year-on-year increase of 8.98%, and a net profit of 371 million yuan, a year-on-year increase of 3.68% [2][4] - The revenue from yeast and deep processing products was 10.854 billion yuan, a year-on-year increase of 14.19%, with a significant increase in sales volume by 15.90% despite a slight decline in average prices [6] - The company’s gross profit margin for 2024 was 23.52%, down 0.67 percentage points year-on-year, while the net profit margin was 8.72%, down 0.65 percentage points year-on-year [6] Market and Product Insights - Domestic revenue reached 9.421 billion yuan, a year-on-year increase of 7.53%, while international revenue was 5.712 billion yuan, a year-on-year increase of 19.36% [6] - The company has actively expanded its marketing efforts, resulting in a slight increase in the number of domestic and international distributors [6] - The company’s sales expense ratio increased slightly due to proactive marketing strategies, while the cost optimization for raw materials began to show effects in Q4 2024 [6] Future Projections - The company expects to enter a new phase of profit growth as the high point of the current raw material price cycle has passed [6] - Forecasts for net profit in the coming years indicate a steady increase, with projected PE ratios decreasing from 18 in 2025 to 14 in 2027 [6]

Group 1 - The company held the 39th meeting of the 9th Board of Directors on January 15, 2025, to approve the proposal for confirming daily related party transactions for 2024 and estimating daily related party transactions for 2025 [1] - From January 1 to March 31, 2025, the company and its subsidiaries engaged in related party transactions with specific amounts detailed in the announcement [1] - The company indicated that the estimated daily related party transactions for 2025 may differ from actual transactions, allowing for adjustments among different related parties under the same control, not exceeding the estimated total amount [2] Group 2 - As of March 31, 2025, the cumulative amount of related party transactions did not exceed the previously estimated total amount [2] - The related party transaction amounts are unaudited and subject to confirmation by the annual audit results [2]